Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Palagyi, Andreas ^a   Neveling, Kornelia ^b   Plinninger, Ursula ^a   Ziesch, Andreas ^a   Targosz, Bianca Sabrina ^c   Denk, Gerald U ^a   Ochs, Stephanie ^a   Rizzani, Antonia ^a   Meier, Daniel ^b   Thasler, Wolfgang E ^a   Hanenberg, Helmut ^d   De Toni, Enrico N ^a   Bassermann, Florian ^c   Schäfer, Claus ^a   Göke, Burkhard ^a   Schindler, Detlev ^b   Gallmeier, Eike ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COMPLEMENTARY DNA; CYTOSINE; DOXORUBICIN; ETOPOSIDE; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP F PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; FLUOROURACIL; MELPHALAN; MITOMYCIN C; RAD51 PROTEIN; THYMINE; FANCC PROTEIN, HUMAN; MESSENGER RNA;

ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN HUH 7; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DNA CROSS LINKING; EPIGENETICS; EXON; FANCONI ANEMIA; GENE IDENTIFICATION; GENE INACTIVATION; GENETIC TRANSCRIPTION; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; NONSENSE MUTATION; PHENOTYPE; PREVALENCE; PROTEIN DEFECT; PROTEIN DEPLETION; PROTEIN FUNCTION; UBIQUITINATION; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETICS; IMMUNOBLOTTING; LIVER TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP C PROTEIN; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMANS; IMMUNOBLOTTING; LIVER NEOPLASMS; RNA, MESSENGER;

EID: 77952685261     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-127     Document Type: Article

References (78)

1. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003, 3:23-34. 10.1038/nrc970, 12509764.
2. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748. 10.1038/nrg2159, 17768402.
3. Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE. Gene-Specific Selection Against Experimental Fanconi Anemia Gene Inactivation in Human Cancer. Cancer Biol Ther 2007, 6:654-660.
4. Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, Steltenpool J, Stone S, Dokal I, Mathew CG, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet 2005, 37:958-963. 10.1038/ng1626, 2704909, 16116422.
5. Levitus M, Joenje H, de Winter JP. The Fanconi anemia pathway of genomic maintenance. Cell Oncol 2006, 28:3-29.
6. Dorsman JC, Levitus M, Rockx D, Rooimans MA, Oostra AB, Haitjema A, Bakker ST, Steltenpool J, Schuler D, Mohan S, et al. Identification of the Fanconi anemia complementation group I gene, FANCI. Cell Oncol 2007, 29:211-218.
7. Sims AE, Spiteri E, Sims RJ, Arita AG, Lach FP, Landers T, Wurm M, Freund M, Neveling K, Hanenberg H, et al. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol 2007, 14:564-567. 10.1038/nsmb1252, 17460694.
8. Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, Elledge SJ. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007, 129:289-301. 10.1016/j.cell.2007.03.009, 2175179, 17412408.
9. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997, 272:31941-31944. 10.1074/jbc.272.51.31941, 9405383.
10. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999, 59:3547-3551.
11. Godthelp BC, Wiegant WW, Waisfisz Q, Medhurst AL, Arwert F, Joenje H, Zdzienicka MZ. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res 2006, 594:39-48.
12. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007, 39:162-164. 10.1038/ng1947, 17200671.
13. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007, 7:937-948. 10.1038/nrc2054, 18034184.
14. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005, 104:2807-2816. 10.1002/cncr.21536, 16284991.
15. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62:3789-3793.
16. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643-646. 10.1126/science.1088759, 14576434.
17. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360-5364.
18. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005, 7:60. 1681605,1681605, 16369438.
19. Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005, 11:7508-7515. 10.1158/1078-0432.CCR-05-1048, 16243825.
20. Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004, 165:651-657. 1618568, 15277238.
21. Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, Petersen G. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005, 65:383-386.
22. Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003, 63:2585-2588.
23. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9:568-574. 10.1038/nm852, 12692539.
24. Tischkowitz M, Ameziane N, Waisfisz Q, De Winter JP, Harris R, Taniguchi T, D'Andrea A, Hodgson SV, Mathew CG, Joenje H. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol 2003, 123:469-471. 10.1046/j.1365-2141.2003.04640.x, 14617007.
25. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 2004, 64:2994-2997. 10.1158/0008-5472.CAN-04-0245, 15126331.
26. Neveling K, Kalb R, Florl AR, Herterich S, Friedl R, Hoehn H, Hader C, Hartmann FH, Nanda I, Steinlein C, et al. Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res 2007, 118:166-176. 10.1159/000108297, 18000367.
27. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004, 23:1000-1004. 10.1038/sj.onc.1207256, 14647419.
28. Gallmeier E, Kern SE. Genetic Pathways of Pancreatic Tumorigenesis. "Disease of the Pancreas: Current Surgical Therapy": Genetic Pathways of Pancreatic Tumorigenesis 2007, Heidelberg: Springer Verlag, Beger H, Cameron JL, Matsuno S.
29. Ameziane N, Chen F, Leemans CR, Brakenhoff RH, Joenje H. No evidence for FANCF gene silencing in head-and-neck squamous cell carcinomas. Cell Oncol 2009, 31:53-56.
30. Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996, 56:490-494.
31. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. 10.1038/nature03443, 15829966.
32. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.
33. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency. Cancer Biol Ther 2005, 4:934-936.
34. Gallmeier E, Kern SE. Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer Biol Ther 2005, 4:703-706.
35. Ashwell S, Zabludoff S. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008, 14:4032-4037. 10.1158/1078-0432.CCR-07-5138, 18593978.
36. Gallmeier E, Calhoun ES, Rago C, Brody JR, Cunningham SC, Hucl T, Gorospe M, Kohli M, Lengauer C, Kern SE. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 2006, 130:2145-2154. 10.1053/j.gastro.2006.03.016, 16762635.
37. Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir K, Kasparkova J, Brabec V, Bachman KE, Kern SE. High-throughput screening identifies novel agents eliciting hypersensitivity in fanconi pathway-deficient cancer cells. Cancer Res 2007, 67:2169-2177. 10.1158/0008-5472.CAN-06-2711, 17332347.
38. Gallmeier E, Kern SE. Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models. Clin Cancer Res 2007, 13:4-10. 10.1158/1078-0432.CCR-06-1637, 17200332.
39. Heijden MS, Brody JR, Kern SE. Functional screen of the fanconi anemia pathway in cancer cells by fancd2 immunoblot. Cancer Biol Ther 2004, 3:534-537. Epub 2004 Jun 2018.
40. Hucl T, Gallmeier E, Kern SE. Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials. Cell Cycle 2007, 6:1336-1341.
41. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004, 18:1958-1963. 10.1101/gad.1196104, 514175, 15314022.
42. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982, 42:3858-3863.
43. Japanese Collection of Research Bioresources. , http://cellbank.nibio.go.jp/
44. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113. 10.1126/science.285.5424.110, 10390360.
45. Gibson RA, Hajianpour A, Murer-Orlando M, Buchwald M, Mathew CG. A nonsense mutation and exon skipping in the Fanconi anaemia group C gene. Hum Mol Genet 1993, 2:797-799. 10.1093/hmg/2.6.797, 7689011.
46. Valentine CR. The association of nonsense codons with exon skipping. Mutat Res 1998, 411:87-117. 10.1016/S1383-5742(98)00010-6, 9806422.
47. The Sanger Institute Cancer Cell Line Project. , http://www.sanger.ac.uk/genetics/CGP/CellLines
48. Calhoun ES, Gallmeier E, Cunningham SC, Eshleman JR, Hruban RH, Kern SE. Copy-number methods dramatically underestimate loss of heterozygosity in cancer. Genes Chromosomes Cancer 2006, 45(11):1070-1. 10.1002/gcc.20365, 16897743.
49. Calhoun ES, Hucl T, Gallmeier E, West KM, Arking DE, Maitra A, Iacobuzio-Donahue CA, Chakravarti A, Hruban RH, Kern SE. Identifying Allelic Loss and Homozygous Deletions in Pancreatic Cancer without Matched Normals Using High-Density Single-Nucleotide Polymorphism Arrays. Cancer Res 2006, 66:7920-7928. 10.1158/0008-5472.CAN-06-0721, 16912165.
50. Greenman CD, Bignell G, Butler A, Edkins S, Hinton J, Beare D, Swamy S, Santarius T, Chen L, Widaa S, et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 11:164-175. 10.1093/biostatistics/kxp045, 2800165, 19837654.
51. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008, 28:160-174.
52. Liew CT, Li HM, Lo KW, Leow CK, Lau WY, Hin LY, Lim BK, Lai PB, Chan JY, Wang XQ, et al. Frequent allelic loss on chromosome 9 in hepatocellular carcinoma. Int J Cancer 1999, 81:319-324. 10.1002/(SICI)1097-0215(19990505)81:3<319::AID-IJC1>3.0.CO;2-K, 10209942.
53. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239-1241. 10.1038/ng1902, 17033622.
54. Rogers CD, Couch FJ, Brune K, Martin ST, Philips J, Murphy KM, Petersen G, Yeo CJ, Hruban RH, Goggins M. Genetics of the FANCA gene in familial pancreatic cancer. J Med Genet 2004, 41:e126. 10.1136/jmg.2004.024851, 1735657, 15591268.
55. Rogers CD, Heijden MS, Brune K, Yeo CJ, Hruban RH, Kern SE, Goggins M. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther 2004, 3:167-169.
56. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217. 10.1126/science.1171202, 2684332, 19264984.
57. Gallmeier E, Hucl T, Winter JM, Kern SE. No mutations identified in the Fanconi Anemia gene BRIP1 (BACH1, FANCJ). NOGO 2005, 10:1.
58. Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, Diotti R, Milton K, Pujara K, Landers T, et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 2007, 67:9591-9596. 10.1158/0008-5472.CAN-07-1501, 17909071.
59. Neveling K, Kalb R, Schindler D. Cancer in Fanconi anemia and Fanconi anemia genes in cancer. Fanconi Anemia - A Paradigmatic disease for the Understanding of Cancer and Aging 2007, 59-78. Basel: Karger, Schindler D, Hoehn H.
60. Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer 2003, 97:425-440. 10.1002/cncr.11046, 12518367.
61. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004, 77:257-267. 10.1002/ajh.20183, 15495253.
62. Johnson FL, Lerner KG, Siegel M, Feagler JR, Majerus PW, Hartmann JR, Thomas ED. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972, 2:1273-1276. 10.1016/S0140-6736(72)92649-9, 4117807.
63. Sweeney EC, Evans DJ. Hepatic lesions in patients treated with synthetic anabolic steriods. J Clin Pathol 1976, 29:626-633. 10.1136/jcp.29.7.626, 476130, 185239.
64. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-442. 10.1053/jhep.2003.50047, 12540794.
65. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006, 23:1535-1547. 10.1111/j.1365-2036.2006.02932.x, 16696801.
66. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607.
67. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763. 10.1053/j.gastro.2008.02.090, 18471552.
68. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, Kaspers GJ, Cloos J, Joenje H, Reinhardt D, Ossenkoppele GJ, et al. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol 2008, 30:299-306.
69. Sinha SM, Singh RD, Alam ND, Roy AD, Roychoudhury SD, Panda CD. Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma. Mol Cancer 2008, 7:84. 10.1186/1476-4598-7-84, 2633285, 18990233.
70. Demuth I, Wlodarski M, Tipping AJ, Morgan NV, de Winter JP, Thiel M, Grasl S, Schindler D, D'Andrea AD, Altay C, et al. Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9. Eur J Hum Genet 2000, 8:861-868. 10.1038/sj.ejhg.5200552, 11093276.
71. Morgan NV, Tipping AJ, Joenje H, Mathew CG. High frequency of large intragenic deletions in the Fanconi anemia group A gene. Am J Hum Genet 1999, 65:1330-1341. 10.1086/302627, 1288285, 10521298.
72. Rischewski JR, Gross M, Hanenberg H, Michael K, Schneppenheim R, Schindler D. Mutation Spectrum of FANCC in Europe and DHLPC-Based Identification of a Large Deletion. Fifteenth Annual Fanconi Anemia Research Fund Scientific Symposium 2003, Houston, TX.
73. Neveling K, Endt D, Hoehn H, Schindler D. Genotype-phenotype correlations in Fanconi anemia. Mutat Res 2009, 668:73-91.
74. Gallmeier E, Winter JM, Cunningham SC, Kahn SR, Kern SE. Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX. Carcinogenesis 2005, 26:1811-1820. 10.1093/carcin/bgi132, 15905198.
75. Gibson RA, Buchwald M, Roberts RG, Mathew CG. Characterisation of the exon structure of the Fanconi anaemia group C gene by vectorette PCR. Hum Mol Genet 1993, 2:35-38. 10.1093/hmg/2.1.35, 8490620.
76. Snyder ER, Ricker JL, Chen Z, Waes CV. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines. Cancer Lett 2007, 245:75-80. 10.1016/j.canlet.2005.12.028, 16466850.
77. The Fanconi Anemia Mutation Database. , http://www.rockefeller.edu/fanconi/mutate
78. Thasler WE, Weiss TS, Schillhorn K, Stoll PT, Irrgang B, Jauch KW. Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank 2003, 4:49-56. 10.1023/A:1026392429112, 15256870.